Abstact
Introduction
Murine sera were obtained and stored at -80℃. The concentrations of IL-10, IFN-γ and IL-17 in serum were determined by use of an enzyme-linked immunosorbent assay (ELISA) kit (Bender MedSystems, Burlingame, CA, USA). Each sample was assayed in triplicate.
Isolation of PBMCs and cell culture
We obtained blood samples from 10 male ACS patients (mean age 54±5 years) with confirmed atherosclerosis by coronary arteriography. Exclusion criteria included: ⑴ ongoing or previous treatment with statins or immunosuppressive drugs, ⑵ hypertension, ⑶ diabetes mellitus, ⑷ hyperlipoidemia, ⑸ smoking, ⑹ cancer, ⑺ chronic immune-mediated disorders, ⑻ liver or kidney disease.
Our institution's Ethics Committee approved the study, and all patients gave their informed written consent for use of blood samples.
Peripheral blood mononuclear cells (PBMCs) were isolated from blood samples and prepared at 1×10 6 cells/ml in RPMI 1640 medium containing 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin without additives (control) or with simvastatin (1 or 10 μM) for 96 hr. The dose of simvastatin was based on the doses used in previous studies (22,23).
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Results

Body weight and biochemical parameters
At the time of sacrifice, simvastatin-treated and control mice did not differ in body weight (P＞0.05), and simvastatin did not alter lipid levels (TC, TG, LDL-C and HDL-C) as compared with control group (P＞0.05, Table 1 ).
Simvastatin upregulated the expression of Foxp3, IL-10 and TGF-β in atherosclerotic plaques
To identify the distribution of Tregs in atherosclerotic plaques, we targeted Foxp3 transcription factor and measured its levels in atherosclerotic lesions.
After 6 weeks of simvastatin treatment, immunohistochemical studies showed an increase in the number of Tregs within atherosclerotic plaque ( Figure 1A) . 
Simvastatin influenced circulatory levels of IL-10, IFN-γ and IL-17
The serum levels of IL-10 were greatly increased in simvastatin group than the control group, but the circulatory levels of IFN-γ and IL-17 were significantly reduced after the simvastatin treatment (P＜0.05, Figure. 4).
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